Ascendis Pharma A/S (NASDAQ:ASND) Price Target Cut to $180.00 by Analysts at Oppenheimer

Ascendis Pharma A/S (NASDAQ:ASND) had its price target decreased by Oppenheimer from $190.00 to $180.00 in a research note issued to investors on Friday morning,Benzinga reports. Oppenheimer currently has an outperform rating on the biotechnology company’s stock.

Several other analysts have also recently commented on ASND. Wells Fargo & Company raised their price objective on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a research note on Tuesday, September 17th. Citigroup raised their price objective on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. StockNews.com cut shares of Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. Evercore ISI raised their price objective on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a research note on Tuesday, September 17th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $170.00 target price on shares of Ascendis Pharma A/S in a research report on Friday. One analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $191.77.

Ascendis Pharma A/S Stock Performance

ASND stock opened at $122.00 on Friday. Ascendis Pharma A/S has a one year low of $90.13 and a one year high of $161.00. The stock has a market capitalization of $7.40 billion, a PE ratio of -15.10 and a beta of 0.66. The company has a fifty day moving average of $132.40 and a 200-day moving average of $132.47.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The company had revenue of $38.75 million for the quarter, compared to analysts’ expectations of $94.74 million. Equities analysts forecast that Ascendis Pharma A/S will post -7.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Hedge funds and other institutional investors have recently modified their holdings of the company. Groupama Asset Managment purchased a new stake in shares of Ascendis Pharma A/S during the third quarter worth about $60,000. Signaturefd LLC grew its holdings in shares of Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after buying an additional 80 shares in the last quarter. Bessemer Group Inc. grew its holdings in shares of Ascendis Pharma A/S by 61.0% during the first quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after buying an additional 332 shares in the last quarter. Searle & CO. purchased a new stake in shares of Ascendis Pharma A/S during the second quarter worth about $205,000. Finally, Rhumbline Advisers grew its holdings in shares of Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after buying an additional 143 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.